Kristina Sonnevi

Publications
CV
Public outreach and news

Selected publications

Journal article: THE LANCET. 2024;403(10441):2293-2306
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Dreyling M; Doorduijn J; Gine E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote V; Shpilberg O; da Silva MG; Leppa S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz R; Celli M; Hess G; Arcaini L; Visco C; van Meerten T; Wirths S; Zinzani PL; Novak U; Herhaus P; Benedetti F; Sonnevi K; Hanoun C; Haenel M; Dierlamm J; Pott C; Klapper W; Goezel D; Schmidt C; Unterhalt M; Ladetto M; Hoster E
Article: LEUKEMIA AND LYMPHOMA. 2024;65(4):534-537
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
Harrysson S; Eloranta S; Ekberg S; Enblad G; Andersson P-O; Sonnevi K; Ljungqvist M; Sander B; Jerkeman M; Smedby KE
Article: LEUKEMIA. 2024;38(2):610-620
Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis
Ren W; Wan H; Abd Own S; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini R-M; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarstrom Q
Article: BLOOD ADVANCES. 2024;8(2):407-415
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Jorgensen RRK; El-Galaly TC; Riise J; Leppa S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I

Articles

Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16_suppl):7015
EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.
Vose J; Vitolo U; Lugtenburg P; Chamuleau MED; Linton KM; Thieblemont C; Sonnevi K; Jurczak W; Olszewski AJ; Awan FT; Okada CY; Feldman TA; Hutchings M; Favaro E; Hoehn D; Li Z; Conlon R; Sancho J-M; Chavez JC
Article: EJHAEM. 2023;4(3):647-655
Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly
Junlen H-R; Sonnevi K; Linden O; Hellstrom M; Scivetti MV; Olsson M; Tufvesson I; Johansson A-S; Wahlin BE
Article: HEMASPHERE. 2023;7(8):e928
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project
Jerkeman M; Ekberg S; Glimelius I; Albertsson-Lindblad A; Entrop JP; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
Article: ISCIENCE. 2023;26(6):106864
ADAR1-mediated RNA editing promotes B cell lymphomagenesis
Pecori R; Ren W; Pirmoradian M; Binder M; Papavasiliou N; Wang X; Liu D; Berglund M; Li W; Tasakis RN; Di Giorgio S; Ye X; Li X; Wu K; Helm D; Arnold A; Wust S; Schneider M; Selvasaravanan K-D; Fuell Y; Stafforst T; Amini R-M; Sonnevi K; Enblad G; Sander B; Wahlin BE; Zhang H; Papavasiliou FN; Pan-Hammarstrom Q
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):476-477
How to choose between curative radiotherapy or chemotherapy in low stage MCL?—a population‐based analysis of outcome in patients with stage I‐II MCL in Sweden
Albertsson‐Lindblad A; Ekberg S; Glimelius I; Ellin F; Sonnevi K; Lewerin C; Smedby KE; Jerkeman M
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:429-430
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Smedby KE; Antonilli S; Enblad G; Sonnevi K; Wahlin BE; Andersson P; Jerkeman M; Eloranta S
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:302-303
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Ren W; Own SA; Wan H; Berglund M; Wang X; Yang M; Li X; Liu D; Sonnevi K; Enblad G; Amini R; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Article: CANCERS. 2023;15(5):1585
2-Arachidonoylglycerol Modulates CXCL12-Mediated Chemotaxis in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Merrien M; Wasik AM; Melen CM; Morsy MHA; Sonnevi K; Junlen H-R; Christensson B; Wahlin BE; Sander B
Article: FRONTIERS IN ONCOLOGY. 2023;13:1176698
Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study
Haider Z; Wasterlid T; Spangberg LD; Rabbani L; Jylha C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hagglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;198(2):267-277
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients
Harrysson S; Eloranta S; Ekberg S; Enblad G; El-Galaly TC; Sander B; Sonnevi K; Andersson P-O; Jerkeman M; Smedby KE
Article: LEUKEMIA AND LYMPHOMA. 2022;63(6):1387-1397
Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia
Melen CM; Merrien M; Wasik AM; Panagiotidis G; Beck O; Sonnevi K; Junlen H-R; Christensson B; Sander B; Wahlin BE
Article: EJHAEM. 2021;2(4):774-784
Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience
Sonnevi K; Ljungqvist M; Joelsson JK; Harrysson S; Wasterlid T; Bernell P; Wahlin BE
Article: BMC CANCER. 2021;21(1):500
The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
Noring K; Carlsten M; Sonnevi K; Wahlin BE
Article: HEMASPHERE. 2021;5(1):e510
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
Eskelund CW; Dimopoulos K; Kolstad A; Glimelius I; Raty R; Gjerdrum LMR; Sonnevi K; Josefsson P; Nilsson-Ehle H; Bentzen HHN; Fagerli UM; Kuittinen O; Haaber J; Niemann CU; Pedersen LB; Larsen MT; Geisler CH; Hutchings M; Jerkeman M; Gronbaek K
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(1):75-81
Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study
Sonnevi K; Wasterlid T; Melen CM; Harrysson S; Smedby KE; Wahlin BE
Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):572
THE CANNABINOID STUDY – 01: INVESTIGATING THE EFFECTS OF CANNABINOIDS IN INDOLENT LEUKEMIC B‐CELL LYMPHOMA
Melén CM; Merrien M; Wasik AM; Sonnevi K; Junlén H; Christensson B; Sander B; Wahlin BE
Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):242
EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH‐RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME
Eskelund CW; Kolstad A; Glimelius I; Räty R; Gjerdrum LR; Sonnevi K; Josefsson P; Nilsson‐Ehle H; Bentzen H; Fagerli U; Kuittinen O; Haaber J; Pedersen LB; Larsen MT; Geisler CH; Hutchings M; Jerkeman M; Grønbæk K
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2019;8:7
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016
Carlsten M; Jadersten M; Hellstrom A; Littmann K; Melen CM; Junlen HR; Sonnevi K; Ljungman P; Bjorkstrand B; Wahlin BE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;175(4):614-622
Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study
Melen CM; Enblad G; Sonnevi K; Junlen HR; Smedby KE; Jerkeman M; Wahlin BE
Article: THROMBOSIS RESEARCH. 2014;133(5):762-767
Risk factors for recurrent venous thromboembolism in young and middle-aged women
Ljungqvist M; Sonnevi K; Bergendal A; Holmstrom M; Kieler H; Larfars G
Article: THROMBOSIS RESEARCH. 2013;132(2):164-169
Self-reported family history in estimating the risk of hormone, surgery and cast related VTE in women
Sonnevi K; Bergendal A; Adami J; Larfars G; Kieler H
Article: BLOOD COAGULATION AND FIBRINOLYSIS. 2013;24(5):547-553
Obesity and thrombin-generation profiles in women with venous thromboembolism
Sonnevi K; Tchaikovski SN; Holmstrom M; Antovic JP; Bremme K; Rosing J; Larfars G
Article: THROMBOSIS AND HAEMOSTASIS. 2011;106(5):901-907
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years
Sonnevi K; Tchaikovski SN; Holmstrom M; Rosing J; Bremme K; Larfars G
Journal article: BLOOD. 2010;116(21):154
High Thrombin Generation Measured In the Presence of Activated Protein C Is Associated with An Increased Risk of Recurrence Among Women 18–64 Years After a First Event of VTE
Sonnevi K; Tchaikovski SN; Bremme K; Holmstrom M; Rosing J; Larfars G
Show more

All other publications

Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16)
EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL
Vose J; Vitolo U; Lugtenburg P; Chamuleau MED; Linton KM; Thieblemont C; Sonnevi K; Jurczak W; Olszewski AJ; Awan FT; Okada CY; Feldman TA; Hutchings M; Favaro E; Hoehn D; Li Z; Conlon R; Sancho J-M; Chavez JC
Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Conference publication: BLOOD. 2022;140:10790
Rituximab Infusion in 30 Minutes' Is Safe and Improves the Flow of Outpatients with Lymphoma Treatment (SPEEDR)
Wahlin BE; Radman T; Ljungqvist M; Sonnevi K
Conference publication: BLOOD. 2021;138:4587
Good Outcome after R-Hyper-CVAD/R-MA in High-Risk Aggressive B-Cell Lymphoma: A Single-Center Experience
Sonnevi K; Ljungqvist M; Joelsson JK; Harrysson S; Wasterlid T; Bernell P; Wahlin B
Preprint: RESEARCH SQUARE. 2020
The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
Noring K; Carlsten M; Sonnevi K; Wahlin B
Conference publication: BLOOD. 2020;136:3-4
Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project
Jerkeman M; Palsdottir T; Glimelius I; Albertsson-Lindblad A; Weibull C; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
Letter: ANNALS OF HEMATOLOGY. 2020;99(3):649-651
Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation
Rassidakis GZ; Stromberg O; Xagoraris I; Jatta K; Sonnevi K
Conference publication: BLOOD. 2019;134:5487
A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma
Melen CM; Merrien M; Wasik A; Sonnevi K; Junlen H-R; Christersson B; Sander B; Wahlin BE
Conference publication: BLOOD. 2018;132:4121
Cannabinoid Receptors and CXCR4 Cross-Talk in Lymphoma Cells
Merrien M; Wasik AM; Melen C; Sonnevi K; Christensson B; Wahlin BE; Sander B
Preprint: SSRN ELECTRONIC JOURNAL. 2018
Morbidity, Mortality and Normality after Autologous Stem-Cell Transplantation for Lymphoma: A Comprehensive, Single-Centre, Population-Based, Real-World Analysis of Patients Transplanted 1994-2016
Carlsten M; Jädersten M; Hellström A; Littmann K; Melén CM; Junlén HR; Sonnevi K; Ljungman P; Björkstrand B; Wahlin B
Conference publication: HAEMATOLOGICA. 2014;99:537
MORTALITY AND CARDIOVASCULAR DISEASE AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM IN YOUNG AND MIDDLE-AGED WOMEN
Ljungqvist M; Sonnevi K; Odeberg J; Holmstrom M; Kieler H; Larfars G
Thesis / dissertation: 2013
Venous thromboembolism in women : risk factors and long term follow-up
Sonnevi, Kristina
Conference publication: BLOOD. 2012;120(21):2250
Obesity Is a Risk Factor for Recurrent Venous Thrombosis in Young and Middle-Aged Women. Results From Tehs-Follow up, a Nested Cohort Study On 1394 Women with VTE
Ljungqvist M; Sonnevi K; Bergendal A; Holmstrom M; Kieler H; Larfars G
Meeting abstract: THROMBOSIS RESEARCH. 2011;127:S140
High BMI is correlated to increased thrombin generation in women, age 18-65 after venous thromboembolism
Sonnevi K; Antovic J; Holmstrom M; Larfars G
Conference publication: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2011;9:632
Thrombin generation profiles and association with obesity and inflammation in women with VTE
Sonnevi K; Tchaikovski S; Holmstrom M; Bremme K; Rosing J; Larfars G
Conference publication: BLOOD. 2010;116(21):72
High Thrombin Generation Measured In the Presence of Activated Protein C Is Associated with An Increased Risk of Recurrence Among Women 18-64 Years After a First Event of VTE
Sonnevi K; Tchaikovski SN; Bremme K; Holmstrom M; Rosing J; Larfars G

Employments

Postdoctoral Studies, Department of Medicine, Huddinge, Karolinska Institutet, 2023-2026

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 2013
University Medical Degree, Karolinska Institutet, 1999

Selected publications

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI